Mayo Clinic Researchers Establish KRAS CtDNA Mutation As Key Prognostic Factor In Pancreatic Cancer

A groundbreaking study conducted by the Mayo Clinic Comprehensive Cancer Center has unveiled that the detection of the KRAS circulating tumor DNA (ctDNA) mutation in the blood and abdominal fluid significantly correlates with an increased risk of cancer metastasis and lower survival rates in individuals with pancreatic ductal adenocarcinoma (PDAC).

This mutation can be identified through tests that are already available and approved for clinical use.

Pancreatic ductal adenocarcinoma, recognized for its aggressive nature, is notoriously hard to diagnose early. Often, by the time it is detected, the cancer has already spread to other body parts.

The lack of effective tests to uncover this spread complicates the process of selecting the most appropriate treatment plan.

Published in the Annals of Surgical Oncology, the findings from this study could revolutionize the way doctors and patients approach treatment, pinpointing those at greater risk of metastasis.

Dr. Mark Truty, a hepatobiliary and pancreatic surgical oncologist at Mayo Clinic's Department of Surgery and the senior author of the study, remarked on the significance of this development. "This is a major advancement for pancreatic ductal adenocarcinoma," he stated.

Dr. Truty highlighted the utility of genetic testing in improving treatment decision-making, emphasizing the newfound understanding of the KRAS status's implications.

This research is based on a prospective cohort study that analyzed nearly 800 patients between 2018 and 2022, making it the most extensive patient series to date regarding ctDNA usage.

The study discovered that 20%-30% of PDAC patients had detectable levels of mutant KRAS ctDNA without having undergone any prior treatment like chemotherapy, suggesting ctDNA assays be conducted before treatment for optimal results.

The analysis of blood samples showed that 104 patients (14%) possessed the KRAS ctDNA mutation, leading to a higher propensity for advanced cancer development and reduced survival rates.

Additionally, the examination of abdominal fluid in 419 patients found that 123 (29%) had the mutation, similarly indicating a dire prognosis.

The presence of the KRAS mutation, whether in blood or abdominal fluid, has been linked to poorer outcomes, underscoring the mutation's role in cancer progression. The data underscore the utility of this test in identifying patients who may not benefit solely from surgery, thereby steering treatment plans towards integrating chemotherapy or radiation before surgical intervention.

For the minority of patients without the KRAS mutation, the test provides less definitive results, necessitating further diagnostic procedures.

Dr. Jennifer Leiting, a hepatobiliary and pancreatic surgeon at Mayo Clinic and the study's first author, explained the historical context of KRAS mutations in pancreatic cancer. She stated, "Historically, we've known that KRAS mutations are associated with a more biologically aggressive pancreatic cancer."

Dr. Leiting further elaborated on the clarity the study brings to interpreting test results for enhancing patient care, highlighting its role in more precise staging and treatment decision-making at the time of diagnosis.

The researchers advocate for incorporating the KRAS ctDNA test into the standard diagnostic process for PDAC patients.

This approach aims to facilitate more tailored risk assessments and effective treatment strategies, offering a beacon of hope for those battling this formidable disease.

Dr. Truty expressed optimism regarding the impact of genetic testing advancements on patient outcomes, stating, "It's optimistic to see how advances in genetic testing are directly helping our patients."